TITLE

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone

AUTHOR(S)
Johnsen, Erik; A.^Kroken, Rune; Wentzel-Larsen, Tore; A.^Jørgensen, Hugo
PUB. DATE
January 2010
SOURCE
BMC Psychiatry;2010, Vol. 10, p26
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: No clear recommendations exist regarding which antipsychotic drug should be prescribed first for a patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head effectiveness of first-line second-generation antipsychotics with regards to time until drug discontinuation, duration of index admission, time until readmission, change of psychopathology scores and tolerability outcomes. Methods: Patients = 18 years of age admitted to the emergency ward for symptoms of psychosis were consecutively randomized to risperidone (n = 53), olanzapine (n = 52), quetiapine (n = 50), or ziprasidone (n = 58), and followed for up to 2 years. Results: A total of 213 patients were included, of which 68% were males. The sample represented a diverse population suffering from psychosis. At admittance the mean Positive and Negative Syndrome Scale (PANSS) total score was 74 points and 44% were antipsychotic drug naïve. The primary intention-to-treat analyses revealed no substantial differences between the drugs regarding the times until discontinuation of initial drug, until discharge from index admission, or until readmission. Quetiapine was superior to risperidone and olanzapine in reducing the PANSS total score and the positive subscore. Quetiapine was superior to the other drugs in decreasing the PANSS general psychopathology subscore; in decreasing the Clinical Global Impression - Severity of Illness scale score (CGI-S); and in increasing the Global Assessment of Functioning - Split version, Functions scale score (GAF-F). Ziprasidone was superior to risperidone in decreasing the PANSS positive symptoms subscore and the CGI-S score, and in increasing the GAF-F score. The drugs performed equally with regards to most tolerability outcomes except a higher increase of hip-circumference per day for olanzapine compared to risperidone, and more galactorrhoea for risperidone compared to the other groups. Conclusions: Quetiapine appears to be a good starting drug candidate in this sample of patients admitted to hospital for symptoms of psychosis. Trial Registration: ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/: NCT00932529.
ACCESSION #
49160257

 

Related Articles

  • Persistence of Extra-pyramindal Disorders and Psychiatric Relapse after Withdrawal of Long-Term Phenothiazine Therapy. Hershon, H. I.; Kennedy, P. F.; McGuire, R. J. // British Journal of Psychiatry;Jan72, Vol. 120 Issue 554, p41 

    The article presents a study on the persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. In this study, sixty-two chronic schizophrenics in hospital were studied, about 32 male and 30 female patients and they had all been on...

  • Antipsychotic Agents May Trigger Insulin Resistance in Children.  // Journal of Psychosocial Nursing & Mental Health Services;Jan2005, Vol. 43 Issue 1, p12 

    Shows that atypical antipsychotic agents commonly used to treat children with aggression, bipolar disorder and schizophrenia may trigger insulin resistance, according to a study conducted by researchers at the Johns Hopkins Children's Center. Methodology of the study; Findings of the study.

  • Partial Compliance with Antipsychotics Increases Mental Health Hospitalizations in Schizophrenic Patients: Analysis of a National Managed Care Database. Kozma, Chris M.; Weiden, Peter J. // American Health & Drug Benefits;Jan2009, Vol. 2 Issue 1, p31 

    Objective: To investigate the relationship between partial compliance with antipsychotic medication and mental health hospitalization in managed care patients with schizophrenia. Study Design: We performed a retrospective evaluation of 1499 outpatients with ≥ 1 anti-psychotic claims and a...

  • A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Chagnon, Y. C.; Mérette, C.; Bouchard, R. H.; Émond, C.; Roy, M.-A.; Maziade, M. // Molecular Psychiatry;Dec2004, Vol. 9 Issue 12, p1067 

    Antipsychotics can induce in schizophrenic (SZ) and bipolar disorder (BP) patients serious body weight changes that increase risk for noncompliance to medication, and risk for cardiovascular diseases and diabetes. A genetic origin for this susceptibility to weight changes has been hypothesized...

  • Case Histories Illustrating the Utility of Sertindole in Clinical Practice. Schuck, Peter; Ameele, Hans van den; Jaanson, Peeter; Ryckmans, Vincent; Hawley, Chris // CNS Drugs;2004 Supplement 2, Vol. 18, p31 

    Many conventional and atypical antipsychotic agents are available for the treatment of schizophrenia. Matching individual patients to the medication that suits them best is often a matter of trial and error. Controlled clinical trials and extensive post-marketing research have shown that the...

  • FLUPHENAZINE.  // Davis's Drug Guide for Nurses, 10th edition;2007, p542 

    This article presents a nursing guide to the antipsychotic agent fluphenazine. Drug information provided includes pharmacokinetics, contraindications or precautions, adverse reactions or side effects, interactions, route or dosage, and availability. Popular brands are Modecate, Modecate...

  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. Ascher-Svanum, Haya; Baojin Zhu; Faries, Douglas; Landbloom, Ron; Swartz, Marvin; Swanson, Jeff // BMC Psychiatry;2006, Vol. 6, p8 

    Background: There is an ongoing debate over whether atypical antipsychotics are more effective than typical antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index...

  • Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre. Tarricone, Ilaria; Casoria, Michela; Gozzi, Beatrice Ferrari; Grieco, Daniela; Menchetti, Marco; Serretti, Alessandro; Ujkaj, Manjola; Pastorelli, Francesca; Berardi, Domenico // BMC Psychiatry;2006, Vol. 6, p11 

    Background: Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA...

  • amisulpride.  // Royal Society of Medicine: Medicines;2002, p52 

    The article provides information on amisulpride, an antipsychotic drug which can be used for the treatment of symptoms of schizophrenia, often in patients who do not respond to, or who can not tolerate, conventional antipsychotic drugs. It is taken orally. Atypical antipsychotics are used with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics